Moreover, in a different meta-analysis evaluating the circulating tumor DNA (ctDNA) in 106 advanced NSCLC patients, the KRAS mutations that were detected signified a worse OS (HR, 2.07; p = <0.01) for the patients treated with chemotherapy [33]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.